Delivering Better^™.

Shankar Hariharan, Ph.D.

Founder & Chief Executive Officer

Dr. Hariharan is the Founder, President, and CEO of Scienture, Inc. Dr. Hariharan has over 35 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses and has held several leadership positions at Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals.

As the Executive Vice President and chief scientific officer at Amneal, he oversaw Global Research and development, Global Regulatory Affairs, and Specialty Product Development. He was instrumental in achieving significant revenue growth (>$1.5B) with high profit margins.

Before joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company’s successful acquisition.

Some notable blockbuster drug products, offering unique value to patients and caregivers, brought to market under Dr. Hariharan’s leadership include Celexa® (>$2B), Lexapro® ($ 4B), Namenda® (>$2B), Megace ES® (>$100M) and over 200 generic products (including many complex generic products). Dr. Hariharan obtained his bachelor’s degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts.

Dr. Hariharan currently serves on the Board of Depymed, Inc. and the Advisory Board of New Rhein Healthcare, LLC and MAA Laboratories.

Narasimhan Mani, Ph.D., MBA

President

Dr. Narasimhan Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. He most recently served as the President & CEO for Kesin Pharma Corporation, a Specialty Pharma company focused on commercializing specialty and brand products. His past roles include serving as the CEO of Xiromed LLC, a Generics and Specialty drug product company, and as the VP of Global Corporate Strategy and BD at Amneal Pharmaceuticals, where he led all the company’s strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial Operations. His previous experiences include being the Corporate Finance and Strategic Planning Leader in the pharmaceutical and medical device sectors at Johnson & Johnson in New Brunswick, NJ. He also worked as a research scientist and product development leader at Forest Laboratories and Par Pharmaceuticals. He continues to be part of the Executives-in-Residence at New Rhein Healthcare Investors, a life-sciences-focused private equity firm. He serves as a Board Member at Corsair Pharma, Inc., one of their portfolio companies.

Dr. Mani’s journey in the pharmaceutical and healthcare sectors began with his B.Pharm (Hons.). from BITS, Pilani, India, which he completed in 1995. His subsequent graduate degrees include an M.S. in Analytical Chemistry from the University of Oklahoma, Norman, in 1998, a Ph.D. in Pharmaceutics from the University of Georgia, Athens, in 2003, and an MBA in Finance and Marketing from Columbia Business School, New York, NY, in 2008. Dr. Mani also received the 2021 Outstanding 50 Asian Americans in Business Award in September 2021.

Rahul Surana, Ph.D., MBA

Executive Vice President & Chief Operating Officer

Dr. Rahul Surana is a seasoned business leader in the healthcare and pharmaceutical industries, with over two decades of expertise spanning corporate strategy, R&D, and business development. At Scienture, Dr. Surana has played a pivotal role in building a robust 505(b)(2) NDA portfolio for the U.S. market focused on cardiovascular and central nervous system diseases. In addition to managing operations, finance, IT, and human resources, he has been instrumental in raising funds through seed rounds, convertible notes, and licensing deals.

Michele Rath

Senior Vice President & Chief Commercial Officer

Michele Rath is a healthcare and pharmaceutical professional with over 25 years of experience in Sales & Marketing, pipeline development, market access strategy, pricing & contracting, and new product launches. She has commercial experience across various drug archetypes, including sterile injectables, oral solids, biosimilars, and branded 505(b)(2) NDA assets. Michele has held a variety of key roles at Cardinal Health, CVS Health (Caremark), Pfizer (Hospira), AuroMedics Pharma (Eugia), and Fresenius Kabi USA, where she managed portfolios for products like Zosyn®, Zyvox®, Diprivan®, Naropin®, and Retacrit® one of Pfizer’s first biosimilars.

She holds a Bachelor of Science in Business Administration from Northern Illinois University.

Shreena Patel

Vice President, Regulatory Affairs & Project Management

A seasoned regulatory professional with over 18 years of experience in handling the submissions of new drug applications and abbreviated new drug applications to the U.S. FDA, Shreena has led cross-functional teams to achieve several 505(j), 505(b)(2), and 505(b)(1) applications in the U.S. for various drug product dosage forms (solid, liquid, topical, nasal, transdermal and injectable products) across a broad range of therapeutic categories. She has efficiently worked on several pre- and post-approval IND, NDA, and ANDA eCTD submissions, including first-to-file opportunities, and worked with multiple Clinical Research Organizations (CROs) to ensure good quality US FDA submissions. Shreena has coordinated several product development meetings, pre-submission, and mid-cycle review meetings with the FDA. She has efficiently managed regulatory staff working in different time zones and worked successfully on defining key product submission strategies based on ICH and FDA guidelines.